NRCT Clinical Study in to Acetaminophen-Induced Liver Injury
Acetaminophen (APAP) (N-acetyl-p-aminophenol) is used to treat moderate to severe pain and release fever, usually in a mixture with other active ingredients in acetaminophen-based medicine [1]. However, APAP overdose leads to serious liver damage. Since 2009, the FDA has started a health campaign against the overdose and abuse of APAP to protect public health. Studies of drug-induced liver injury due to overdose of APAP have revealed the presence of biomarkers in patients’ blood, such as the expression of specific mRNA [2]. Therefore, the FDA has begun a clinical trial in the younger population to collect data about these markers to assess the risk of this mechanism of APAP-induced liver injury in young people. This paper exposes the rationale and the design of an ongoing multicenter NCTR study to analyze biomarkers for drug-induced liver injury in children and adolescents who were excessively exposed to APAP.
Global Health Corresponder
8yThank You, Claudette